Exporting cosmetics to the USA requires compliance with FDA requirements for cosmetics that apply equally to domestic and imported products. Understanding FDA requirements for cosmetics, including MoCRA obligations, is essential before shipping or selling in the U.S. market.
FDA requirements for cosmetics cover product classification, safety, ingredients, labeling, facility and product obligations, and import compliance. Cosmetics are defined under the Federal Food, Drug, and Cosmetic Act as articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. They are not subject to premarket approval by the FDA, with the important exception of color additives.
Imported cosmetics must meet the same standards as products manufactured in the United States. They must not be adulterated or misbranded. This means they must be safe under labeled or customary conditions of use, properly labeled, and free of prohibited or restricted ingredients. Color additives must be approved for the intended use, and some require batch certification. At the border, FDA and Customs and Border Protection examine entries for labeling, color additive compliance, and other regulatory issues. Exporting cosmetics to USA successfully therefore begins with treating U.S. rules as mandatory rather than optional.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) significantly expanded FDA authority over cosmetics. Before MoCRA, facility registration and product listing were largely voluntary. MoCRA made facility registration and product listing mandatory for most cosmetic products marketed in the United States.
Key changes include mandatory facility registration (with biennial renewal), mandatory product listing (with annual updates), adverse event reporting requirements, safety substantiation expectations, and expanded FDA enforcement tools such as the ability to suspend a facility’s registration under certain conditions. MoCRA also directed FDA to develop good manufacturing practice regulations and fragrance allergen labeling rules. Certain small businesses may qualify for exemptions from facility registration, product listing, and GMP requirements, but these exemptions do not apply to products that regularly contact the mucous membrane of the eye or to certain other categories. Understanding MoCRA requirements is now central to FDA cosmetic regulations for any brand intending to sell in the U.S. market.
Under MoCRA, owners or operators of facilities that manufacture or process cosmetic products for distribution in the United States must register those facilities with FDA. Registration is submitted through the Cosmetics Direct electronic portal (or alternative accepted methods) and must be renewed every two years. Foreign facilities that manufacture or process cosmetics for the U.S. market are included and typically must designate a U.S. agent.
Separately, the responsible person-defined as the manufacturer, packer, or distributor whose name appears on the product label—must list each marketed cosmetic product with FDA. Product listing includes the product name, category, full ingredient list, and the associated facility. Listings must be updated annually and when significant changes occur.
It is critical to understand that facility registration and product listing are not FDA approval. FDA does not issue certificates verifying compliance with registration or listing, and assignment of a registration or listing number does not mean the agency has approved the facility or the product. Small-business exemptions exist but must be carefully evaluated against current FDA criteria and product type.
FDA requires that cosmetics be safe for consumers under labeled or customary conditions of use. Companies are expected to substantiate safety. Certain ingredients are prohibited or restricted. Color additives form a special category: they must be approved by FDA for the specific intended use, and many require certification of individual batches.
Product claims determine regulatory classification. If labeling or marketing suggests the product is intended to treat, prevent, mitigate, or cure disease, or to affect the structure or function of the body beyond cosmetic purposes, the product may be regulated as a drug (or both a drug and a cosmetic). Such products then fall under additional drug requirements. Exporters must therefore review both formula and claims carefully. FDA requirements for imported cosmetics apply the same safety, ingredient, and claims standards that apply to U.S.-made products.
U.S. cosmetic labeling requirements are detailed and must be met before products enter the market. The principal display panel generally requires an identity statement and a net quantity of contents declaration. The information panel must include an ingredient declaration in descending order of predominance (using appropriate names), and the name and place of business of the manufacturer, packer, or distributor.
Labels must be in English (with limited exceptions such as Puerto Rico). Country-of-origin marking is also required under U.S. customs rules. Warning statements may be required for certain product types. Claims must not render the product misbranded. Because labeling is examined at import, non-compliant labels are a frequent cause of detention or refusal. Preparing US cosmetic labeling requirements correctly before export reduces clearance risk.
Several recurring mistakes undermine compliance. One of the most serious is using “FDA approved” or similar language for cosmetics. FDA does not approve cosmetic products (except for color additives under specific rules), and such claims can render labeling false or misleading.
Another common error is treating facility registration or product listing as equivalent to product approval. Registration and listing create obligations and visibility for FDA; they do not constitute endorsement. Labeling and claims mistakes—especially drug-like claims on products intended only as cosmetics—can reclassify the product and trigger additional requirements or enforcement. Finally, some exporters overlook MoCRA facility registration and product listing obligations, particularly when relying on contract manufacturers or assuming prior voluntary programs remain sufficient. These gaps increase the risk of import problems and enforcement actions.
Get Practical Guidance on FDA Cosmetic Requirements Through MultiMe + StrongBody AI
Navigating FDA requirements for cosmetics, MoCRA obligations, and product-market fit questions benefits from structured support. MultiMe and StrongBody AI help sellers organize the product and market problem clearly, identify which regulatory topics require verification (facility status, product listing, labeling, claims, color additives), and recognize when specialized regulatory counsel or a U.S. agent is needed. The platforms support information organization and professional communication so that compliance discussions can proceed on a clearer factual basis rather than scattered assumptions.
Why FDA-ready Cosmetic Brands Benefit from Selling Through StrongBody AI + MultiMe
Once core FDA and MoCRA obligations are understood and addressed, brands still need market access and commercial infrastructure. StrongBody AI provides a health- and beauty-oriented marketplace presence that aligns with the positioning of many cosmetic products. MultiMe complements this with global discovery tools, multilingual communication, structured Offers, and transaction support. Together they allow sellers to reach international health and beauty customers without having to build an entire go-to-market stack from scratch, while keeping product information and commercial interactions organized.
Understand your FDA and MoCRA obligations first—facility registration, product listing, safety, ingredients, labeling, and claims—then build a market-ready cosmetic presence. Reach global health and beauty customers through StrongBody AI and MultiMe while maintaining clearer control over product information and international sales communication.
Read Next
Selling Dietary Supplements in the EU
